Try our beta test site
1103 studies found for:    "Hodgkin lymphoma"
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Proton Therapy for Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Radiation: Proton Radiation Plan;   Radiation: Conventional Photon Radiation Plan;   Radiation: Intensity Modulated Radiation Plan
2 Completed
Has Results
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: PLX3397
3 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
4 Recruiting Brazilian Prospective Hodgkin Lymphoma Registry
Conditions: Hodgkin Lymphoma;   Hodgkin Disease
Intervention:
5 Recruiting A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab Vedotin
6 Completed A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: entinostat (SNDX-275)
7 Active, not recruiting
Has Results
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Condition: Hodgkin's Lymphoma
Interventions: Drug: Adriamycin®;   Drug: Vinblastine;   Drug: Nitrogen Mustard;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Bleomycin;   Drug: Etoposide;   Drug: Prednisone;   Biological: G-CSF;   Procedure: Radiotherapy
8 Unknown  Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
9 Terminated Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
10 Unknown  Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Interventions: Drug: R-mabHDI and ABVD;   Drug: ABVD
11 Recruiting HD17 for Intermediate Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);   Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine);   Radiation: 30Gy IF-RT (Involved-Field Radiotherapy);   Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)
12 Active, not recruiting HD16 for Early Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine);   Radiation: 20 Gy IFRT (Involved Field Radiotherapy)
13 Completed Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.
Condition: Hodgkin Lymphoma
Intervention: Other: PET/CT post 2 cycles of chemotherapy
14 Active, not recruiting Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: dose dense ABVD
15 Recruiting GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM13
16 Recruiting Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Adriamycin;   Drug: Dacarbazine
17 Completed Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients
Conditions: Hodgkin Lymphoma;   Hodgkin Disease
Intervention: Drug: triptorelin
18 Active, not recruiting Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin;   Drug: ABVD
19 Unknown  Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention:
20 Completed INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
Conditions: Refractory Hodgkin Lymphoma;   Recurrent Adult Hodgkin's Lymphoma
Interventions: Drug: INCB040093 Monotherapy;   Drug: INCB040093;   Drug: itacitinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.